MedTrace Logo

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

NCT07219927 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-10-22

No results posted yet for this study

Summary

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Conditions

  • Parkinson Disease

Interventions

OTHER

Observational study

Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM)

Sponsors & Collaborators

  • Supernus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Mindy Grall, PhD ANP-BC · Supernus Pharmaceuticals, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-08-01
Completion
2027-08-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07219927 on ClinicalTrials.gov